ArticleAnalytical science advances2025
Evaluation of the Ligand-Independent Activation of a VHH-Based Anti-CD19 SynNotch Receptor by Dual-Luciferase Assay.
Article in Analytical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Evaluation of the Ligand-Independent Activation of a VHH-Based Anti-CD19 SynNotch Receptor by Dual-Luciferase Assay.Analytical science advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ligand-independent activation poses a significant challenge for synthetic receptors, limiting their dynamic range. Given the difficulties and inconsistencies in evaluating this crucial aspect in many studies, we utilized a dual-luciferase assay to assess the background activity of the SynNotch receptor. These receptors are modular, orthogonal constructs designed to detect and respond to specific extracellular signals by expressing a targeted protein. In this study, we engineered an anti-CD19 SynNotch receptor by incorporating a nanobody into the antigen-binding domain, leveraging the advantageous properties of camelid VHHs. We then evaluated the performance of the final construct, focusing on its functionality and ligand-independent activation using the dual-luciferase assay. The results revealed that although reporter expression significantly increased in the presence of the antigen, there was also a high level of background expression, which could hinder the performance of the SynNotch receptor. Additionally, the SynNotch receptor exhibited a 24-h delay in reaching its peak activation level in response to the antigen and in returning to baseline levels in its absence. Therefore, the optimization of the SynNotch construct is essential to enhance the receptor's dynamic range.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.